DE60015965D1 - Wirkstoffkombinationen enthaltend (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid und einen inhibitor, inducer oder substrat von p450 isoenzym 3a4 - Google Patents
Wirkstoffkombinationen enthaltend (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid und einen inhibitor, inducer oder substrat von p450 isoenzym 3a4Info
- Publication number
- DE60015965D1 DE60015965D1 DE60015965T DE60015965T DE60015965D1 DE 60015965 D1 DE60015965 D1 DE 60015965D1 DE 60015965 T DE60015965 T DE 60015965T DE 60015965 T DE60015965 T DE 60015965T DE 60015965 D1 DE60015965 D1 DE 60015965D1
- Authority
- DE
- Germany
- Prior art keywords
- isoenzym
- dihydroxyh
- inducer
- methylsulfonyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
GB9902593 | 1999-02-06 | ||
GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
GB9921064 | 1999-09-08 | ||
GB9921063 | 1999-09-08 | ||
PCT/GB2000/000278 WO2000045817A1 (en) | 1999-02-06 | 2000-02-01 | Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60015965D1 true DE60015965D1 (de) | 2004-12-23 |
DE60015965T2 DE60015965T2 (de) | 2006-01-05 |
Family
ID=27269637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60015965T Expired - Lifetime DE60015965T2 (de) | 1999-02-06 | 2000-02-01 | Wirkstoffkombinationen enthaltend (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid und einen inhibitor, inducer oder substrat von p450 isoenzym 3a4 |
Country Status (29)
Country | Link |
---|---|
US (3) | US6982157B1 (de) |
EP (1) | EP1185274B1 (de) |
JP (2) | JP2002536331A (de) |
KR (2) | KR20060117381A (de) |
CN (1) | CN1165310C (de) |
AR (1) | AR029333A1 (de) |
AT (1) | ATE282415T1 (de) |
AU (1) | AU767304B2 (de) |
BR (1) | BR0007999A (de) |
CA (1) | CA2358632C (de) |
CZ (1) | CZ301296B6 (de) |
DE (1) | DE60015965T2 (de) |
EE (1) | EE04929B1 (de) |
EG (1) | EG23858A (de) |
ES (1) | ES2232418T3 (de) |
GB (1) | GB0000710D0 (de) |
HK (1) | HK1041817A1 (de) |
ID (1) | ID30485A (de) |
IL (1) | IL144715A0 (de) |
IS (1) | IS2337B (de) |
MX (1) | MXPA01007905A (de) |
MY (1) | MY130606A (de) |
NO (1) | NO320745B1 (de) |
NZ (1) | NZ512982A (de) |
PL (1) | PL198034B1 (de) |
PT (1) | PT1185274E (de) |
TR (1) | TR200102228T2 (de) |
TW (1) | TWI282738B (de) |
WO (1) | WO2000045817A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
KR20060085686A (ko) | 2003-10-10 | 2006-07-27 | 라이프사이클 파마 에이/에스 | 피브레이트를 포함하는 고형 제제 |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
BRPI0514189A (pt) | 2004-08-06 | 2008-06-03 | Transform Pharmaceuticals Inc | composições farmacêuticas de estatina e métodos de tratamento relacionados |
US20090162316A1 (en) | 2005-07-05 | 2009-06-25 | Harvard University | Liver targeted conjugates |
JP5235676B2 (ja) * | 2005-12-20 | 2013-07-10 | レツク・フアーマシユーテイカルズ・デー・デー | (e)−7−〔4−(4−フルオロフェニル)−6−イソプロピル−2−〔メチル(メチルスルホニル)アミノ〕ピリミジン−5−イル〕−(3r,5s)−3,5−ジヒドロキシヘプタ−6−エン酸を含む医薬組成物 |
US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
JP7470647B2 (ja) * | 2018-06-14 | 2024-04-18 | アストラゼネカ・ユーケイ・リミテッド | ジヒドロピリジン型カルシウムチャネル遮断薬医薬組成物を用いて血圧を低下させるための方法 |
AU2020320448A1 (en) | 2019-07-31 | 2022-02-17 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition comprising HMG-CoA reductase inhibitors and fenofibrate |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
ES2065113T3 (es) * | 1991-07-02 | 1995-02-01 | Benckiser Gmbh Joh A | Botella de almacenamiento plegable. |
JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
US6576660B1 (en) * | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-01 EP EP00901264A patent/EP1185274B1/de not_active Expired - Lifetime
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Application Discontinuation
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko active Search and Examination
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Application Discontinuation
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2002
- 2002-05-08 HK HK02103512A patent/HK1041817A1/xx unknown
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60015965D1 (de) | Wirkstoffkombinationen enthaltend (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid und einen inhibitor, inducer oder substrat von p450 isoenzym 3a4 | |
IS2820B (is) | Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru | |
IS8478A (is) | Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess | |
EE200100430A (et) | Tert-butüül-(E)-(6-[2-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüülsulfonüül)amino]pürimidiin-5-üül]vinüül](4R,6S)-2,2-dimetüül[1,3]dioksaan-4-üül)atsetaadi valmistamismeetod | |
EE05586B1 (et) | Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees | |
DE60140581D1 (de) | Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure | |
CA2429263A1 (en) | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia | |
NO20061181L (no) | Krystallformer av kalsiumslatet til Bis [(E)-7-[4-(4-Fluorfenyl)-6-Isopro -6-lsopropyl-2- [Metyfonyl) Amino] Pyrimidin-5-YL] (3R, 5S) -3,5-Dihydroksyhept-6-ensyre] | |
HUP0104977A3 (en) | Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 | |
SI1185274T1 (en) | Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 | |
DK1185274T3 (da) | Lægemiddelkombinationer omfattende (E) - 7 -[4- (4-fluorphenyl) - 6 - isopropyl-2 [methyl(methylsulfonyl)amino ]-pyrimidin-5-yl] (3R,5S) - 3,5-dihydroxyhept-6-ensyre og en inhibitor af, en inducer af eller et substrat for P450 isoenzym 3A4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |